NCT04897763
Assessment of safEty, Tolerability, Radiation Dosimetry, and Imaging Properties of 89Zr-labeled giRenTuximab (89Zr-Girentuximab) in patIents With Non-musclE-iNvasive Bladder CancEr (NMIBC)
Phase: Early Phase 1
Role: Collaborator
Start: Oct 1, 2021
Completion: Sep 26, 2022